TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35389367

Group type: EXPERIMENTAL
Intervention: CareHand app (tailored exercise program, self-management and monitoring tools)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CareHand app
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (written home exercise routine and recommendations)
Number of subjects: 36
Study: 34210333

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention (2-year multilevel intervention including counseling sessions and text messages)
Number of subjects: 4484

Group type: EXPERIMENTAL
Intervention: Feel4Diabetes-intervention
Number of subjects: 4484

Group type: COMPARATOR
Intervention: Control group (standard care including medical check-up results and lifestyle recommendations)
Number of subjects: 4484
Study: 32898170

Group type: EXPERIMENTAL
Intervention: Intramuscular stimulation with a 12-week rehabilitation program (n = 25)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham intramuscular stimulation with a 12-week rehabilitation program (n = 19)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rehabilitation program alone (control group) (n = 8)
Number of subjects: 52
Study: 35046201

Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 64

Group type: COMPARATOR
Intervention: LMA Protector
Number of subjects: 64
Study: 34217654

Group type: EXPERIMENTAL
Intervention: Class I recommendation for ICD implantation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: LVEFs ≤35%
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: LVEFs >35%
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement
Number of subjects: 188
Study: 36355382

Group type: EXPERIMENTAL
Intervention: MRI-based screening using combined targeted and standard biopsies
Number of subjects: 1532

Group type: COMPARATOR
Intervention: Standard biopsies alone
Number of subjects: 1532

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1532
Study: 34499574

Group type: EXPERIMENTAL
Intervention: Recombinant rabies G protein vaccine
Number of subjects: 800

Group type: COMPARATOR
Intervention: Reference vaccine (five-dose WHO prequalified vaccine)
Number of subjects: 800
Study: 32246050

Group type: EXPERIMENTAL
Intervention: Anemia prevalence
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Anemia prevalence by gender
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Mean hemoglobin levels
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Prevalence of anemia severity
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Factors associated with anemia
Number of subjects: 1415
Study: 32744902

Group type: EXPERIMENTAL
Intervention: Secretion above 25 mL (drainage longer than 24 hours)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Secretion below 25 mL (drainage less than 24 hours)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Overall risk of postoperative infection
Number of subjects: 205
Study: 35868138

Group type: EXPERIMENTAL
Intervention: Aromatherapy (lavender, eucalyptus, or rose oil)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Su Jok (using buckwheat seed)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Su Jok and Aromatherapy (combined)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 120
Study: 33770483

Group type: COMPARATOR
Intervention: ABVD group
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: 2 + 2 group
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: non-randomised 2 + 2 group
Number of subjects: 1686
Study: 35564533

Group type: EXPERIMENTAL
Intervention: Air purifier device (professional XXl inn‐561 innoliving) with HEPA 14 filter
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group (without filtering device)
Number of subjects: 80
Study: 34305584

Group type: EXPERIMENTAL
Intervention: Elaeagnus angustifolia (15 g of the whole fruit powder)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (7.5 g isomalt + 7.5 g cornstarch)
Number of subjects: 58
Study: 34086524

Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stretching exercise
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of kinesiotaping and stretching
Number of subjects: 30
Study: 33030304

Group type: EXPERIMENTAL
Intervention: High fat (85%), 15% protein, essentially carbohydrate-free (CHO-free) diet for 72 hours
Number of subjects: 7

Group type: COMPARATOR
Intervention: Standard mixed (control) diet (30% fat: 15% protein: 55% carbohydrate)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Fasting for 72 hours
Number of subjects: 7
Study: 35200566

Group type: EXPERIMENTAL
Intervention: TEMPO (dyadic, web-based psychosocial and physical activity self-management program)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 49
Study: 32925909

Group type: EXPERIMENTAL
Intervention: Pay-for-performance (P4P) scheme for LARC advice
Number of subjects: 3281667
Study: 35791905

Group type: EXPERIMENTAL
Intervention: Desflurane-based anesthesia (Group D)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Propofol-based anesthesia (Group P)
Number of subjects: 73
Study: 33705612

Group type: EXPERIMENTAL
Intervention: Combined SMWLM + PINS
Number of subjects: 60

Group type: COMPARATOR
Intervention: SMWLM
Number of subjects: 60

Group type: COMPARATOR
Intervention: PINS
Number of subjects: 60
Study: 35170783

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg administered every night for 24 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo administered every night for 24 weeks
Number of subjects: 92
Study: 34369908

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice a day + Lamivudine 150 mg twice a day + Zidovudine 300 mg twice a day
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg four times a day + Lamivudine 150 mg twice a day + Zidovudine 300 mg twice a day
Number of subjects: 408

Group type: COMPARATOR
Intervention: Both interventions (Raltegravir and Efavirenz)
Number of subjects: 408
Study: 32727302

Group type: EXPERIMENTAL
Intervention: ICT group
Number of subjects: 532

Group type: COMPARATOR
Intervention: no-ICT group
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: highest utilization tertile
Number of subjects: 532
Study: 34253086

Group type: EXPERIMENTAL
Intervention: Gossypium mustelinum introgression line IL9
Number of subjects: 2

Group type: COMPARATOR
Intervention: Recurrent parent PD94042
Number of subjects: 2
Study: 32629079

Group type: EXPERIMENTAL
Intervention: Atlas-based ABM segmentation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Custom ABM segmentation
Number of subjects: 176
Study: 34730000

Group type: EXPERIMENTAL
Intervention: COMPASS‐TC (Comprehensive Post‐Acute Stroke Services Transitional Care)
Number of subjects: 2262

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2262
Study: 34598676

Group type: EXPERIMENTAL
Intervention: 60 mg Trimetazidine (TMZ) 12 hours before surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32093778

Group type: EXPERIMENTAL
Intervention: Active case-finding (ACF) using a seed-and-recruit model
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Active case-finding (ACF) targeting household and neighborhood contacts
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Active case-finding (ACF) targeting persons aged ≥ 55 years using mobile screening units
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive case finding (PCF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All interventions (ACF and PCF)
Number of subjects: 8
Study: 35636232

Group type: EXPERIMENTAL
Intervention: MI training (six-months training in Motivational Interviewing)
Number of subjects: 36
Study: 32102086

Group type: EXPERIMENTAL
Intervention: Fezolinetant 15, 30, 60, 90 mg BID or 30, 60, 120 mg QD
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 36243831

Group type: EXPERIMENTAL
Intervention: Graded exercise test (GXT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Submaximal verification bout
Number of subjects: 10
Study: 34373282

Group type: EXPERIMENTAL
Intervention: 177Lu‐PSMA‐617
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cabazitaxel chemotherapy
Number of subjects: 15
Study: 35676218

Group type: EXPERIMENTAL
Intervention: 10-week music-based neurological rehabilitation (MBNR)
Number of subjects: 40
Study: 34364265

Group type: EXPERIMENTAL
Intervention: Yacon flour (25 g daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no yacon flour)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (yacon flour and control)
Number of subjects: 26
Study: 80244778

Group type: EXPERIMENTAL
Intervention: Tar/zinc pyrithione shampoo
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo shampoo
Number of subjects: 70
Study: 35288097

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO) for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laterally wedged insole (LWI) for 6 weeks
Number of subjects: 20
Study: 35333373

Group type: EXPERIMENTAL
Intervention: STAND+ intervention (with sit-stand workstation)
Number of subjects: 630

Group type: COMPARATOR
Intervention: MOVE+ intervention (without sit-stand workstation)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 630
Study: 34285360

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) tube insertion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Orogastric (OG) tube insertion
Number of subjects: 50
Study: 34634757

Group type: EXPERIMENTAL
Intervention: Complex intervention to reduce sedentary behaviour, details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities implemented and adapted over 6 months, details on specific activities not specified.
Number of subjects: 0
Study: 37962288

Group type: EXPERIMENTAL
Intervention: PASCAL
Number of subjects: 300

Group type: COMPARATOR
Intervention: MitraClip
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study: 34106974

Group type: EXPERIMENTAL
Intervention: Problem-solving skills intervention delivered through 6 monthly sessions
Number of subjects: 64
Study: 33151154

Group type: EXPERIMENTAL
Intervention: My Diabetes Coach (MDC) program
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 187
Study: 35460239

Group type: EXPERIMENTAL
Intervention: Mindfulness Yoga
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional Stretching Exercises
Number of subjects: 138
Study: 33400348

Group type: EXPERIMENTAL
Intervention: Topiroxostat 40–160 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Febuxostat 10–60 mg/day
Number of subjects: 0
Study: 34609671

Group type: EXPERIMENTAL
Intervention: Pseudoexfoliation syndrome (PXS) group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-PXS group
Number of subjects: 81
Study: 616172822

Group type: EXPERIMENTAL
Intervention: Diltiazem-retard
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ivabradine (Coraxan)
Number of subjects: 67
Study: 33509845

Group type: EXPERIMENTAL
Intervention: Antibiotic-loaded bone cement (ALBC)
Number of subjects: 9172

Group type: COMPARATOR
Intervention: Plain bone cement
Number of subjects: 9172
Study: 32253081

Group type: EXPERIMENTAL
Intervention: Split x-jaw planning technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open x-jaw planning technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Limited x-jaw planning technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Split and open techniques
Number of subjects: 20
Study: 35679047

Group type: EXPERIMENTAL
Intervention: Multiplex PCR point‐of‐care testing for respiratory pathogens (18 respiratory viruses and 3 bacteria, results ready within 70 minutes)
Number of subjects: 1243

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Multiplex PCR point‐of‐care testing for respiratory pathogens
Number of subjects: 1243
Study: 33180331

Group type: EXPERIMENTAL
Intervention: Driving skill program (10 classroom sessions of 1 hour and 10 on-road sessions of 50 minutes)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (one education class about safe driving)
Number of subjects: 159
Study: 34629006

Group type: EXPERIMENTAL
Intervention: word-problem intervention (n = 56)
Number of subjects: 76

Group type: COMPARATOR
Intervention: business-as-usual comparison (n = 20)
Number of subjects: 76
Study: 33221788

Group type: EXPERIMENTAL
Intervention: Psychoeducation program (8-week duration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no treatment during the same period)
Number of subjects: 80
Study: 37676426

Group type: EXPERIMENTAL
Intervention: AIDRS
Number of subjects: 32
Study: 34303445

Group type: EXPERIMENTAL
Intervention: Organization intervention
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Active treatment conditions
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 148
Study: 32538291

Group type: EXPERIMENTAL
Intervention: CYP2D6 intermediate metabolizers (n = 6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CYP2B6 G516T T/T (n = 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (normal and ultrarapid metabolizers)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All volunteers
Number of subjects: 24
Study: 35874579

Group type: EXPERIMENTAL
Intervention: Colostrum (C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 96
Study: 33500267

Group type: EXPERIMENTAL
Intervention: Dorsiflexion group (group D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neutral group (group N)
Number of subjects: 120
Study: 34342742

Group type: EXPERIMENTAL
Intervention: Community-informed, online HIV prevention intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Existing HIV websites (control group)
Number of subjects: 154
Study: 34081649

Group type: EXPERIMENTAL
Intervention: Telerehabilitation by a low vision therapist using video conferencing
Number of subjects: 57

Group type: COMPARATOR
Intervention: At home self-training provided by the device manufacturer
Number of subjects: 57
Study: 36120805

Group type: EXPERIMENTAL
Intervention: Cold Atmospheric Plasma (CAP) technology, treated biweekly for five sessions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 18
Study: 34399847

Group type: EXPERIMENTAL
Intervention: CBT‐VR (Cognitive Behavioural Therapy and Vestibular Rehabilitation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: VR only (Vestibular Rehabilitation)
Number of subjects: 40
Study: 33605575

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 mins)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS (control)
Number of subjects: 20
Study: 34611132

Group type: EXPERIMENTAL
Intervention: Baseline level of Fetuin-B
Number of subjects: 143
Study: 36179772

Group type: EXPERIMENTAL
Intervention: Good adherence to oral anticoagulants (OACs) defined as proportion of days covered (PDC) >80%
Number of subjects: 778

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs) among adherent patients
Number of subjects: 778

Group type: COMPARATOR
Intervention: Direct oral anticoagulants (DOACs) among adherent patients
Number of subjects: 778
Study: 32020765

Group type: EXPERIMENTAL
Intervention: DACC-coated dressings
Number of subjects: 246

Group type: COMPARATOR
Intervention: Alginate dressings
Number of subjects: 246
Study: 35016403

Group type: EXPERIMENTAL
Intervention: Nursing based on the Roy adaptation model
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine nursing measures
Number of subjects: 120
Study: 32886138

Group type: EXPERIMENTAL
Intervention: Aquabeam® system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostate artery embolization (PAE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 0
Study: 36195934

Group type: EXPERIMENTAL
Intervention: Heart Coherence Exercise (HCE)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Natural Relaxation (NR)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Virtual TSST
Number of subjects: 84

Group type: COMPARATOR
Intervention: Real TSST
Number of subjects: 84
Study: 34112149

Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate eye drops (two drops, one drop every 5 min)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide eye drops (four drops, one drop every 5 min)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Comparison between cyclopentolate and tropicamide groups
Number of subjects: 300
Study: 32792543

Group type: EXPERIMENTAL
Intervention: Improvement of hygiene scale
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Boiling raw milk before consumption
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Urban households
Number of subjects: 196
Study: 35296534

Group type: EXPERIMENTAL
Intervention: Guselkumab Q4W (100 mg at weeks 0, 4, then every 4 weeks)
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Guselkumab Q8W (100 mg at weeks 0, 4, then every 8 weeks)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study: 32291275

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 888

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 888
Study: 35331307

Group type: EXPERIMENTAL
Intervention: 1% povidone iodine
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine
Number of subjects: 375

Group type: COMPARATOR
Intervention: No irrigation (control)
Number of subjects: 375
Study: 33865507

Group type: EXPERIMENTAL
Intervention: Ravidasvir (200 mg once daily) plus Sofosbuvir (400 mg once daily) for 12 weeks (no cirrhosis) or 24 weeks (with cirrhosis)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ravidasvir plus Sofosbuvir
Number of subjects: 301
Study: 35466343

Group type: EXPERIMENTAL
Intervention: Visual alignment leveling method
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Laser device leveling method
Number of subjects: 36

Group type: COMPARATOR
Intervention: Transducer taped to the upper arm
Number of subjects: 36

Group type: COMPARATOR
Intervention: Transducer next to the upper arm taped to a rolled cloth
Number of subjects: 36

Group type: COMPARATOR
Intervention: Transducer at the wrist
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control condition (transducer on intravenous pole)
Number of subjects: 36
Study: 34290558

Group type: EXPERIMENTAL
Intervention: Functional PF brace (Study Group, SG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Neoprene sleeve for the knee (Control Group, CG)
Number of subjects: 38
Study: 35984478

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard of Care (POC group)
Number of subjects: 185
Study: 35507912

Group type: EXPERIMENTAL
Intervention: Booster vaccination with 5, 10, and 20 μg hepatitis B vaccines or 5 μg hepatitis A and B (HAB) combination vaccine with a 0-1-6-month schedule (schedule 2 group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Booster vaccination for anti-HBs positive subjects (schedule 1 group)
Number of subjects: 102
Study: 32949374

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenalidomide and dexamethasone (Rd)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rd alone
Number of subjects: 52
Study: 35977863

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg
Number of subjects: 97
Study: 33509275

Group type: EXPERIMENTAL
Intervention: Implementation of REMAP-COVID trial procedures into routine care processes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote consent and enrollment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coordination with the central institutional review board
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol adherence, adverse event monitoring, and data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Establishment of a centralized institutional process
Number of subjects: 0
Study: 33008287

Group type: EXPERIMENTAL
Intervention: NAC genes under salt stress
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: NAC genes under drought stress
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Cultivated peanut NAC genes under both stresses
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: RT-qPCR analysis of NAC genes
Number of subjects: 160
Study: 35620884

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mother's heartbeat sounds
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Breast milk odour
Number of subjects: 90
Study: 33894146

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 32314514

Group type: EXPERIMENTAL
Intervention: Aloe extract treatment for 4 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control treatment (inulin) for 4 weeks
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aloe treatment responders (n = 33, 39%)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control treatment responders (n = 34, 45%)
Number of subjects: 160
Study: 35821950

Group type: EXPERIMENTAL
Intervention: Preoperative educational video
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Preoperative educational video and postoperative acceptance and commitment therapy (ACT)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group, no perioperative counseling
Number of subjects: 183
Study: 34108673

Group type: EXPERIMENTAL
Intervention: AHSCT
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 49
Study: 32334553

Group type: EXPERIMENTAL
Intervention: Self-administered drug intake supported by a family member
Number of subjects: 385

Group type: COMPARATOR
Intervention: Clinical DOT at Outpatient-TB-centres
Number of subjects: 385
Study: 33244615

Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound (US) for managing tube thoracostomy (TT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chest X-ray (CXR) for managing tube thoracostomy (TT)
Number of subjects: 61
Study: 33356422

Group type: EXPERIMENTAL
Intervention: Irinotecan and cetuximab with vemurafenib (960 mg PO twice daily)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Irinotecan and cetuximab without vemurafenib
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Irinotecan and cetuximab with vemurafenib
Number of subjects: 106